Phase 5 · Immune peptide research

Thymosin Alpha-1 vs LL-37

Thymosin alpha-1 and LL-37 are both immune-active peptides, but they are biologically and clinically distinct: thymosin alpha-1 has human studies in immune-related conditions such as chronic hepatitis B, while LL-37 is chiefly an innate antimicrobial/wound-healing research peptide with very limited clinical evidence; neither is FDA-approved in the U.S.

The short answer

Different does not automatically mean better.

Side AThymosin alpha-1 (TA1)

Side BLL-37

Side-by-side

What actually separates them

Compare

Thymosin alpha-1 (TA1)

LL-37

Identity

Thymosin alpha-1 (TA1)A 28-amino-acid thymic peptide analog (thymalfasin).

LL-37A 37-amino-acid human cathelicidin antimicrobial peptide.

Mechanism

Thymosin alpha-1 (TA1)Immunomodulatory signaling affecting innate and adaptive immune responses.

LL-37Direct antimicrobial, immunomodulatory, and wound-signaling activities that can also be inflammatory.

Evidence

Thymosin alpha-1 (TA1)Randomized trials have studied chronic hepatitis B, with mixed/older evidence and context-specific outcomes.

LL-37A placebo-controlled study assessed topical LL-37 in hard-to-heal venous leg ulcers; systemic safety and broader efficacy remain uncertain.

U.S. status

Thymosin alpha-1 (TA1)No FDA-approved TA1 drug product; FDA flags peptide-impurity and immunogenicity concerns for compounded TA1.

LL-37No FDA-approved LL-37 drug product; FDA says it lacks sufficient safety information to know whether human administration would cause harm.

Main studied context

Thymosin alpha-1 (TA1)Chronic viral hepatitis and other immune-related research settings.

LL-37Local wound-healing and host-defense research.

Key limitation

Thymosin alpha-1 (TA1)Immune modulation does not establish benefit for “immune boosting,” infections, cancer, or general wellness.

LL-37Antimicrobial activity in vitro does not establish safe, effective systemic infection treatment.

Evidence check

Known, unknown, and easy to misread

What the evidence shows

A randomized chronic-hepatitis-B trial reported virologic-response differences with TA1, but modern treatment context and generalizability must be considered.

What it does not prove

A multicenter placebo-controlled trial evaluated LL-37 for venous leg ulcers; that is not evidence for injected LL-37 or treatment of acute infection.

How to read it

FDA identifies material concerns for compounded TA1 and says it lacks adequate safety information for LL-37 administration in humans.

Beginner bottom line

Quick questions

Frequently asked questions

Is TA1 an FDA-approved immune booster?

No; “immune boosting” is not an FDA-approved indication for TA1 in the U.S.

Can LL-37 replace antibiotics or wound care?

No. Suspected infection or a non-healing wound needs prompt clinical assessment.

Are the two peptides interchangeable?

No; their sequences, roles, studied conditions, and evidence differ substantially.

Check the evidence

Primary and official sources

Want to examine the evidence with the community?

Bring a study, ask a focused question, or compare interpretations in Research Discussions.

Visit Research Discussions